Xianmin Song, MD

Quick facts

Phase 2 pipeline

• Blinatumomab plus Reduced-dose Chemotherapy · Oncology
  Blinatumomab targets CD19 and CD3 on T cells, leading to T cell activation and killing of B cell malignancies.
• Venetoclax plus RIC

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Xianmin Song, MD portfolio CI brief
• Xianmin Song, MD pipeline updates RSS